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ABSTRACT 
Extracellular hemoglobin (Hb), a byproduct of hemolysis, can release its prosthetic heme groups upon 
oxidation. This produces metabolically active heme that is exchangeable between acceptor proteins, 
macromolecules and low molecular weight ligands, termed here labile heme. As it accumulates in 
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plasma labile heme acts in a pro-oxidant manner and regulates cellular metabolism while exerting 
pro-inflammatory and cytotoxic effects that foster the pathogenesis of hemolytic diseases. Here we 
developed and characterized a panel of heme-specific single domain antibodies (sdAbs) that together 
with a cellular-based heme reporter assay, allow for quantification and characterization of labile heme 
in plasma during hemolytic conditions. Using these approaches we demonstrate that labile heme 
generated during hemolytic conditions is bound to plasma molecules with an affinity higher than 10-7 
M and that 2-8% (~2-5 µM) of the total amount of heme detected in plasma can be internalized by 
bystander cells, i.e. bioavailable heme. Acute, but not chronic, hemolysis is associated with transient 
reduction of plasma heme binding capacity (HBC1/2), that is, the ability of plasma molecules to bind 
labile heme with an affinity higher than 10-7M. The heme-specific sdAbs neutralize the pro-oxidant 
activity of soluble heme in vitro, suggesting that these maybe used to counter the pathologic effects of 
labile heme during hemolytic conditions. Finally, we show that heme-specific sdAbs can be used to 
visualize cellular heme. In conclusion, we describe a panel of heme-specific sdAbs that when used 
with other approaches provide novel insights to the pathophysiology of heme.  
 
INTRODUCTION 
Heme consists of a tetrapyrrole ring bound to iron (Fe) via several nitrogens. Heme exists essentially 
as a prosthetic group of hemoproteins [1], including hemoglobin (Hb) [2], where Fe binds to the 
gaseous molecules oxygen (O2), nitric oxide (NO) [3] or carbon monoxide (CO) [4] via effective 
back-donation of Fe dπx electrons to low-lying π
* orbitals of these diatomic molecules. Heme displays 
subtle chemical modifications, giving rise to the different types, mainly the a, b and c variants [5]. 
The most common and abundant heme type in mammals is heme b present in Hb and myoglobin, 
among other hemoprotein. Whereas heme c can bind covalently to proteins via two thioester bonds, 
heme b and a cannot and are released from hemoproteins, such as observed upon Hb oxidation [6-9]. 
While often referred as “free heme” [10, 11], the heme released from hemoproteins is most probably 
never in “free form”. Labile heme is the term used to refer to the pool of metabolically active heme, 
which is loosely bound to acceptor proteins, therefore becoming exchangeable with other 
macromolecules and low molecular weight ligands [12]. Of note, while heme is a stable molecule, the 
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term “labile” is used to emphasis that “labile heme” is more readily prone to alteration of its redox 
state, imposed by its immediate environment. 
In adult humans, the sheer number of red blood cells (RBC; ~2-3x1013) coupled to their high Hb 
(~3x108 molecules/RBC) and heme (~1.2x109 molecules/RBC)[13] content create a situation in which  
clinically silent levels of intravascular hemolysis can be associated with the release of relatively high 
amounts of Hb into plasma. Upon oxidation, extracellular Hb can release its non-covalently bound 
heme groups [6-9], generating pro-oxidant labile heme [8, 14, 15] that acts as a alarmin [16], sensed 
by pattern recognition receptors, such as Toll like receptor 4 (TLR4)[17] or  NACHT, LRR and PYD 
domains-containing protein 3 (NALP3) [18]. This endows labile heme with pro-inflammatory [16-
20], vasoactive [21] and cytotoxic [10, 22-25] effects, while also regulating metabolism [26] and 
interfering with coagulation [27]. Presumably these pathophysiologic effects of labile heme contribute 
critically to the pathogenesis of hemolytic conditions, such as malaria caused upon infection by the 
protozoan parasites of the genus Plasmodium [6, 28], severe sepsis caused by polymicrobial infections 
[10] or sickle cell disease caused by mutations in the gene encoding the  chain of Hb [21, 29, 30]. 
Current limitations in methodologies allowing for accurate quantification of labile heme or 
providing further information on its biological environment make it particularly challenging to 
ascertain the contribution of labile heme to the pathogenesis of hemolytic conditions. Here we 
developed a panel of heme-specific single domain antibodies (sdAb) that, when used together with 
other approaches [31], allow to quantify and characterize labile heme in plasma, its rate of cellular 
internalization and cellular localization. We report that intravascular hemolysis in mice is associated 
with the accumulation of labile heme in plasma, which is bound to plasma molecules with an affinity 
higher than 10-7 M. We estimate that about 2-8% (~2-5 µM) of the heme released in plasma during 
hemolytic conditions becomes “bioavailable”, being internalized by bystander cells. Heme-specific 
sdAb can be used to neutralize the pro-oxidant effect of labile heme in solution, an effect that could 
have therapeutic implications in the treatment of infectious as well as non-infectious hemolytic 
conditions. Finally, we demonstrate that heme-specific sdAb can be used to monitor intracellular 
heme, detected primarily in the mitochondria. 
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RESULTS 
Generation of heme-specific SdAbs 
We screened a synthetic phage-display sdAb library [32], derived from a highly soluble and stable VL 
scaffold [33] against heme b, biotinylated in a single carboxylic group, corresponding to a molecular 
weight of 969.2 Da (Fig. 1A,B). Phages encoding sdAb recognizing biotinylated heme were selected 
using streptavidin-magnetic beads (Fig. 1C,D), essentially as described [34]. An ELISA, using non-
biotinylated heme as a solid phase antigen, was used to determine the relative heme-binding capacity 
of the selected sdAb. Relative heme recognition was normalized to the relative amount of sdAb, as 
detected  by ELISA, using a monoclonal antibody (mAb) against the human influenza hemagglutinin 
(HA) epitope expressed in the C-terminus of these sdAb. Eleven sdAbs were selected through this 
assay (Fig. 1E), expressed in E. coli BL21 and purified under denaturing conditions before refolding 
by step-wise dialysis [35]. Protein yield was typically around 10 mg/L with >90% purity, as assessed 
by SDS-PAGE (Fig. 1E). Expression of the ~15 kDa protein corresponding to the full-length sdAb 
containing the MKKTAIAIAVALAGFATV leader peptide sequence and a ~13kDa protein 
corresponding to the leaderless sdAb, was confirmed by western blot (Fig. 1E).  
We then compared the relative capacity of the purified sdAbs used at the same concentration to 
bind a solid-phase heme in an ELISA (Fig. 1F). The affinity (KD) of these sdAb towards heme was 
determine by surface plasmon resonance and estimated to be in the order of 10-7 M, with the exception 
of sdAb 1E4, which has an affinity of 10-5M towards heme (Fig. 1G). Further in silico analyses 
revealed that the complementarity-determining region (CDR) 1 of all the selected sdAbs carries 
potential heme binding motifs [36], including cysteine-X-X-cysteine-Lysine (CXXCK; were X is any 
amino acid (aa)) characteristic of hemoproteins that bind heme c [37], CK, i.e. sdAb 1A6, CN, i.e. 
sdAb 2H7 or CS, i.e. sdAb 2H10, 1G3, 2A12, 1C2 and 2H5, characteristic of hemoproteins that bind 
heme b (Fig. 1G). Based on their heme affinity and the presence of putative heme binding motifs we 
selected the sdAbs 1A6, 2H7 and 2H10 for further analyzes. Of note, CDR3 sequences where absent 
in these sdAbs. 
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SdAbs specificity 
To determine the relative specificity of sdAbs 1A6, 2H7 and 2H10, these were pre-incubated with a 
variety of heme-related molecules and their capacity to bind solid-phase bound heme was assessed by 
ELISA. Heme (FePP) was used a positive control, gallium protoporphyrin (PP) IX (GaPP) as a non-
Fe metallated porphyrin containing redox inert gallium instead of Fe and PP IX (PP) as metal-free 
precursor of heme. As expected, pre-incubation with FePP abolished subsequent recognition of solid-
phase bound heme by all three sdAbs (Fig. 2A). Pre-incubation with PP inhibited heme recognition by 
sdAb 1A6 but not by sdAbs 2H7 and 2H10 (Fig. 2A). This suggests that Fe, present in FePP but not in 
PP, is required for heme recognition by sdAbs 2H7 and 2H10 but not by the sdAb 1A6. Pre-
incubation with GaPP abolished heme recognition by all three sdAbs (Fig. 2A). Given that gallium is 
not readily reduced, mimicking Fe3+, this observation suggests that all three sdAbs recognize 
preferentially oxidized Fe3+PP, consistent with their initial selection under aerobic conditions favoring 
heme oxidation into Fe3+PP. To assess the relative contribution of the porphyrin side chains to heme 
recognition, the sdAb were pre-incubated with Fe deuteroporphyrin IX (DeutP), a synthetic heme 
derivative lacking the heme vinyl group or with FePP IX dimethyl ester chloride (FePPCH3) in which 
the two-propionate side chains are methylated (Fig. 2B). While DeutP inhibited heme recognition by 
all three sdAb (Fig. 2B), FePPCH3 inhibited heme recognition by sdAb 1A6 and 2H7 but only to a 
lesser extent by sdAb 2H10. This suggests that heme recognition by sdAb 2H10 involves a carboxylic 
acid in the propionate side chains (Fig. 2B). 
Pre-incubation with biliverdin or bilirubin, a direct and an indirect end product of heme 
catabolism, respectively, partially inhibited heme recognition by sdAb 1A6 but not by sdAb 2H10 
(Fig. 2C). Recognition of solid-phase bound heme by the sdAb 2H7 was partially inhibited by 
biliverdin but not by bilirubin (Fig. 2C). This suggests that the sdAb 2H10 is probably the only one, 
among these three sdAbs, that recognizes specifically heme. This is consistent with the preferred V-
shaped ridge tile conformation of bilirubin [38], being quite distinct from heme and as such unlikely 
to be recognized by the same linear aa  motif used to recognize heme in 2H10 sdAb. 
We then asked whether these sdAbs recognize porphyrins containing divalent metals, other than 
Fe, such as tin PP (SnPP), cobalt PP (CoPP) or Zinc PP (ZnPP). Pre-incubation of sdAbs 1A6, 2H7 
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and 2H10 with SnPP or CoPP inhibited their binding to solid-phase bound heme (Fig. 3A), while pre-
incubation with ZnPP inhibited heme recognition by sdAb 2H7 but not by sdAb 1A6 and 2H10 (Fig. 
3A). This suggests that the chemical properties of the metal at the center of the protoporphyrin ring 
may be important for heme recognition by sdAb 1A6 and 2H10 but not by sdAb 2H7. 
We also asked whether these sdAbs recognized Fe in the absence of a porphyrin ring. Pre-
incubation with Fe2(SO4)3 failed to inhibit the recognition of solid-phase-bound heme by all three 
sdAbs (Fig. 3B), suggesting that Fe per se is not required for heme recognition by these sdAb. Finally, 
we asked whether these sdAbs recognize heme contained inside hemoproteins. Pre-incubation of the 
sdAbs with Hb, oxidized Hb (MetHb), myoglobin (Mb), albumin bound to heme b or cytochrome c 
failed to inhibit the recognition of solid-phase bound heme by all three sdAbs (Fig. 3C). This suggests 
that while these sdAbs recognize soluble heme they fail to recognize heme when it is incorporate in 
hemoproteins. Table 1 summarizes these results. 
 
Structural characterization of sdAbs-heme complexes 
We used a heme-biotin pull-down assay to compare the relative capacity of sdAbs 1A6, 2H7 and 
2H10 to recognize heme in solution. All three sdAbs bound heme-biotin in solution, with 1A6 and 
2H10 showing higher binding capacity, as compared to 2H7 (Fig. 4A), consistent with their relative 
affinity towards heme (Fig. 1G). 
We used UV-visible spectroscopy to monitor heme (Fig. 4B) and heme binding to sdAbs (Fig. 
4C). The UV-visible spectrum of heme (Fig. 4B) shows two overlapping bands, at ~ 363 and 383 nm, 
in the Soret region and a charge transfer band at 622 nm, indicating high spin Fe3+ state. The UV-
visible spectrum of sdAb bound to heme shows a δ band at 360 nm, an intense Soret band at 412 nm, 
two weak Q bands at 530 and 565 nm and another 624 nm band in the charge transfer region (Fig. 
4C). The Soret band indicates the presence of Fe3+, the 530 and 565 nm bands are consistent with the 
presence of a six-coordinated low spin Fe3+ state, the δ band at 360 nm suggests the presence of a thiol 
axial heme ligation [39] and the 624 nm band is indicative of either Cys or porphyrin to high spin Fe3+ 
charge transfer (Fig. 4C). With the exception of the charge transfer band, UV-visible features of the 
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sdAb/heme complex are similar to the spectra of ferric cytochrome P450cam, carrying Cys and H2O 
axial ligands [40]. 
Heme binding was associated with alterations in the secondary structure of the sdAb, as assessed 
by circular dichroism (CD) and Attenuated total reflection Fourier Transform infrared (ATR-FTIR) 
spectroscopies for sdAb 2H10. Namely, the far-UV CD spectrum revealed a negative band centered at 
218 nm, indicative of a β-sheet protein fold (Fig. 4D). Heme binding resulted in broadening of this 
band, suggesting a conformational rearrangement of secondary structure elements (Fig. 4D). Analysis 
of the Soret region reflects heme coordination with the appearance of a positive CD band at 412 nm, 
absent in apo-2H10 sdAb (Fig. 4D, inset). 
The impact of heme coordination on the secondary structure of sdAb 2H10 was further analyzed 
by ATR-FTIR, which is sensitive to different types of β-sheet structures. A comparison of the 
absorption spectra of sdAb 2H10 in the presence/absence of heme, in the amide I region (1700-1610 
cm-1) is indicative of structural alterations upon heme coordination (Fig. 4E, top). Second derivative 
analysis of the ATR-FTIR spectra, performed to identify individual components under the 
intrinsically broad amide I band envelope [41], revealed major contributions typical of β-sheet 
structures for apo-2H10, in agreement with CD data (Fig. 4E, bottom). The presence of 1633 and 
1693 cm-1 bands simultaneously is most likely associated with an anti-parallel arrangement of β-
strands in sdAb 2H10, which are typically characterized by a strong band at ~1630 cm-1 and a weaker 
one at ~1690 cm-1. Upon heme ligation, there was a rearrangement in β structures with the β-turn band 
at 1668 cm-1 shifting to 1678 cm-1 and a lack of the contribution at 1693 cm-1, which denotes a loss of 
the anti-parallel β-sheet fingerprint. Thus, the sdAb 2H10 is likely composed of anti-parallel β-sheets, 
which undergo conformational changes upon heme binding.  
Resonance Raman (RR) spectroscopy was used to further characterize the heme moiety in the 
sdAb heme-2H10 complex. Upon excitation into the Soret electronic transition band, RR spectra 
display in the high frequency region (1300-1700cm-1) core size marker bands (e.g. ν4, ν3, ν2 and ν10), 
which are sensitive to coordination, spin and redox state of the heme Fe. A comparison of RR spectra 
of hemin versus the sdAb-heme complex (Fig. 4F) demonstrates that the sdAb 2H10 binds in a 
specific manner to heme b, revealed by changes in frequency and relative intensity of spin state 
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sensitive ν3, ν2 and ν10 modes. Also, the bandwidth of the well-defined ν3 mode revealed one spin 
species (i.e. one type of ligation) in the complex. The ν4 at 1377 and
 1373 cm-1 in the heme-2H10 
complex and heme, respectively, indicate in both cases a Fe3+ state of the heme-Fe. The heme-2H10 
complex revealed the ν3 and ν2 at 1508 and 1585 cm
-1 respectively, characteristic for six-coordinated 
low spin heme Fe (Fig. 4F). These modes were found at 1492 and 1571 cm-1, respectively in the heme 
spectra, indicating a five-coordinated high spin (Fig. 4F) state, with most likely a Cl- ion acting as the 
fifth axial ligand. The most probable candidates for heme axial ligands in the six-coordinated low spin 
2H10-heme complex are tyrosine (Y) and lysine (K), besides cysteine (C), as established by the UV-
Vis spectra. These aa are present in the CDR1 of sdAb 2H10 (Fig. 1G) as well as axial ligands in 
several hemoproteins [36]. Also, the H2O molecule, which in some heme proteins acts as a strong 
axial ligand, cannot be excluded. 
We then analyzed the effect of pH on sdAb binding to heme. Heme binding by sdAb 2H10 was 
inhibited at pH 4.0-4.5 (Fig. 5A). Restoring pH to 7.0 reestablished heme recognition by sdAb 2H10, 
despite some level of sdAb precipitation (Fig. 5B). We also addressed whether Ca2+ or Mg2+ interfere 
with heme binding by this sdAb. We found that heme-binding to sdAb 2H10 was impaired by Ca2+ 
but not by Mg2+ (Fig. 5C,D). This suggest that while divalent metals, such as Fe2+ or Mg2+, do not 
appear to interfere with sdAb binding to heme, Ca2+ can modulate heme binding to the sdAb 2H10.  
 
Characterization of labile heme in plasma during hemolytic conditions 
Induction of acute hemolysis in C57BL/6 mice, by the administration of phenylhydrazine, was 
associated with a marked reduction of circulating RBC numbers (Fig. 6A) and increased heme 
concentration in plasma (Fig. 6B), i.e. from 23,4 ± 7,1 µM at steady state [29] to 120,8 ± 26,6 µM, 24 
hours after phenylhydrazine administration (Fig. 6B). There was negative correlation between the 
number of circulating RBC and the concentration of heme in plasma, that is, lower numbers of 
circulating RBC were associated with higher concentration of heme in plasma (Fig. 6C). 
Heme accumulation in plasma, 24 hours after phenylhydrazine administration, was associated with 
heme uptake by bystander cells, i.e. 4.8 ± 0.6 µM (Fig. 6D), as assessed in vitro using a cellular heme 
reporter assay [12, 31]. Briefly, HEK293 cells transiently transfected with horseradish peroxidase 
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based reporter were exposed to mouse plasma, containing an unknown amount of heme that that can 
be internalized, as reveled by the acquisition of intracellular HRP activity. By comparison with a 
standard curve of soluble heme one can infer on the amount of bioavailable heme in plasma and 
estimate it to correspond to about 4% of the total amount of heme detected in the plasma of these mice 
(Fig. 6D). There was a negative correlation between the number of circulating RBC and the 
concentration of bioavailable heme in plasma, that is, the lower the number of circulating RBC the 
higher the concentration of bioavailable heme in plasma (Fig. 6E). 
We developed a sandwich ELISA to quantify heme in solution, using solid-phase bound sdAb 1A6 
to capture soluble heme and biotinylated 2H7 sdAb to detect heme bound to the sdAb 1A6. The assay 
quantifies heme in solution, in a linear range from 0.15 to 2.5 µM(Fig. 6F). Using this sdAb-based 
ELISA we did not detect heme in the plasma of C57BL/6 mice subjected phenylhydrazine 
administration (data not shown). However, considering that the heme-specific sdAbs have an affinity 
of 10-7 M towards heme (Fig. 1G), the ELISA should detect only heme not bound to other molecule 
with an affinity higher than 10-7 M. This suggests therefore that the bioavailable heme detected in the 
plasma of C57BL/6 mice receiving phenylhydrazine is bound to plasma molecules with an affinity 
higher than 10-7 M. In keeping with this notion, the same ELISA also did not recognize heme bound 
to HPX (Fig. 6G). 
We then asked whether plasma proteins with high affinity towards heme, such as HPX, can uptake 
heme bound to the heme-specific sdAb. We confirmed that HPX can take-up heme from the sdAb 
2H10, using an in vitro pull-down assay with streptavidin-beads capturing biotinylated-heme bound to 
sdAb 2H10, in the presence or absence of HPX (Fig. 6H). Namely when apo-HPX is added to the 
sdAb 2H10 bound to biotinylated-heme, the streptavidin-beads pull-down both the sdAb 2H10 and 
the HPX, revealing that HPX removed the biotinylated-heme from the sdAb 2H10 (Fig. 6H). 
We adapted the heme-specific ELISA to quantify the relative capacity of plasma macromolecules 
or other low molecular ligands to bind heme with an affinity higher than 10-7 M, that is, the plasma 
heme binding capacity (HBC1/2). Briefly, Plasma is incubated in vitro with increasing concentrations 
of heme, until saturation of heme-binding molecules with an affinity towards heme higher than 10-7 
M. The heme-specific sdAb-based ELISA is used, as described above, to detect excess heme and the 
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concentration of heme required to reduce by 50% the plasma HBC is defined as HBC1/2. Induction of 
acute hemolysis reduced the HBC1/2 of C57BL/6 mice, from 23.8±1.9 mM at steady state to 16.7±2.1 
mM within 6 hours of phenylhydrazine administration, returning to steady state levels by 12 hours 
(Fig. 6I). This suggests that the majority of labile heme generated during acute hemolysis is readily 
bound by plasma molecules with an affinity >10-7 M and cleared thereafter. 
We then asked whether chronic hemolysis induced by Plasmodium infection is associated with the 
detection of labile heme in plasma. Infection of C57BL/6 mice with Plasmodium chabaudi chabaudi 
(Pcc) was associated with a progressive increase in the number of infected RBC until day 7, 
decreasing thereafter until day 9 post-infection (Fig. 7A). The peak of infection was associated with 
heme accumulation in plasma, i.e. 237,8±28,2 µM, decreasing thereafter to return to basal levels 9 
days post-infection (Fig. 7B). There was a positive correlation between the percentage of infected 
RBC and the concentration of heme in plasma, with higher percentage of infected RBC associated 
with higher concentration of heme in plasma (Fig. 7C). Plasmodium infection was not associated with 
a reduction of plasma HBC1/2 (Fig. 7D) and the levels of labile heme detected by the sdAb-based 
ELISA remained above 0.15 µM (data not shown). Nevertheless, 1-2% of heme detected in plasma at 
day 7 post infection, i.e. 3.9 ± 0.3 µM, became bioavailable, as assessed in vitro using a cellular heme 
reporter assay (Fig. 7E). There was a positive correlation between the percentage of infected RBC and 
the concentration of bioavailable heme in plasma (Fig. 7F). While this confirms that the blood stage 
of Plasmodium infection is associated with the accumulation high levels of heme in plasma [6, 10, 11, 
22, 28, 42], labile heme is bound to plasma molecules with an affinity higher than 10-7 M, and 
therefore cannot be detected by the sdAb-based ELISA. A proportion of the labile heme that 
accumulates in plasma is bioavailable and therefore likely to participate in the pathogenesis of severe 
forms of malaria [6, 10, 11, 22, 28, 42]. 
We then asked whether the development of chronic hemolysis caused by the sickle Hb mutation, is 
associated with the accumulation of labile heme in plasma. We tested this hypothesis in knock-in 
C57BL/6;129 hα/hα::βS/βS mice, a well-established experimental model of sickle-cell disease [43]. 
Heme concentration in the plasma of C57BL/6;129 hα/hα::βS/βS knock-in mice was 27.0±3.9 µM, as 
compared to 18.5±3.9 µM and 19.9±3.4 µM in control C57BL/6;129 hα/hα::βA/βS and hα/hα::βA/βA 
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mice that do not develop sickle cell disease, respectively (Fig. 8A). There was no apparent reduction 
of plasma HBC1/2 in hα/hα::β
S/βS mice, as compared to control hα/hα::βA/βS or hα/hα::βA/βA mice (Fig. 
8B). Detection of labile heme, using the sdAb-based ELISA, remained above 0.15 µM (data not 
shown). Nevertheless, about 8% of the heme detected in the plasma of hα/hα::βS/βS mice became 
bioavailable, i.e. 2.1±0.9 µM, as assessed in vitro using a cellular heme reporter assay (Fig. 8C). This 
was not the case in control hα/hα::βA/βA or hα/hα::βA/βS mice (Fig. 8C). This confirms that sickle cell 
disease is associated with the accumulation of labile heme in plasma [21, 30, 44, 45] and supports the 
notion that labile heme promotes the pathogenesis of this hemolytic condition [21, 30, 44, 45]. 
 
Heme-specific sdAb modulate the redox activity of labile heme  
We assessed whether heme binding by sdAb 2H10 interferes with the redox activity of labile heme, as 
assessed by electron exchange between heme and ascorbic acid in the presence of H2O2. Heme 
catalyzed ascorbic acid oxidation in a dose-dependent manner, that is, higher heme concentrations (0-
5 µM) depleted ascorbate, as detected by HPLC (Fig. 9A, B). This pro-oxidant effect of heme was 
attenuated by sdAb 2H10, as compared to equimolar concentrations of control sdAb or human serum 
albumin (HSA) (Fig. 9A). Importantly, sdAb 2H10 also inhibited the pro-oxidant activity of 
heme/H2O2 in a concentration-dependent manner that is higher sdAb concentrations reduced ascorbate 
depletion (Fig. 9B). At each concentration tested, the sdAb 2H10 was more effective than the control 
sdAb or HSA in terms of preventing heme-driven ascorbate depletion (Fig. 9B). 
 
Heme-specific SdAbs detect cellular heme 
We asked whether heme-specific sdAbs can be used to detect intracellular heme by 
immunofluorescence and/or by flow cytometry. Intracellular heme was detected by 
immunofluorescence, in the perinuclear area of HeLa cells, using sdAb 1A6, 2H7 and 2H10, as 
compared to a control sdAb (Fig. 10A). Intracellular heme was also detected by flow cytometry using 
the same sdAbs (Fig. 10B). Detection of intracellular heme by the sdAb 2H10 was suppressed when 
the sdAb was pre-incubated with increasing heme concentrations, as assessed by flow cytometry (Fig. 
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10C) or by immunofluorescence (Fig. 10D). Pre-incubation of sdAb 2H10 with PP failed to inhibit 
intracellular heme detection by flow cytometry (Fig. 10E). 
 Having established that the heme-specific sdAbs can be used to detect intracellular heme, we 
addressed in more detail the intracellular localization of heme. Detection of intracellular heme by 
sdAb 2H10 overlapped with mitochondria staining by MitoTracker (Fig. 10F) and to a minor extent 
with endoplasmic reticulum (ER) staining by an anti-Calnexin monoclonal Ab (mAb) (Fig. 11A) or 
with early endosome staining by an anti-early endosome antigen 1 (EEA-1) staining (Fig. 11B), as 
detected by confocal microscopy. There was no overlap between heme and actin staining (Fig. 11C) 
and some minimal level of heme co-localization with heme oxygenase-1 (HO-1) (Fig. 11D) and 
bilirubin (Fig. 11E). 
 
DISCUSSION 
About 75-80% of bioavailable Fe in mammals is contained within the prosthetic heme groups of 
hemoproteins, with Hb containing the major pool of heme [25]. Extracellular Hb and heme are 
scavenged in plasma by haptoglobin and HPX, respectively [46]. Presumably accumulation of labile 
heme in plasma only takes place once the scavenging capacity of haptoglobin and HPX are saturated 
[10, 11, 16, 47, 48]. When this occurs, labile heme acts in a pro-oxidant [49, 50], pro-inflammatory 
[17, 51], vasoactive [21] and cytotoxic [10, 22, 23] manner that contributes to the pathogenesis of 
hemolytic conditions [11, 52], such as illustrated for malaria [6, 28], severe sepsis [10] or sickle cell 
disease [21, 29, 30]. However, the relative lack of analytical methods providing an accurate 
characterization of labile heme in plasma makes it difficult to prove unequivocally its direct 
involvement in the pathogenesis of these diseases. Here we generated and characterized a panel of 
heme-specific sdAbs (Fig. 1-5) providing a more accurate characterization of labile heme.  
We reasoned that to detect specifically labile heme in plasma, heme-specific sdAbs should 
recognize heme not bound to Hb, HPX, high- or low-density lipoprotein or albumin. Therefore, the 
affinity of the sdAbs towards heme should be lower to the one displayed by Hb (10-14 M)[53], HPX 
(10-12-10-13 M)[54, 55], high- or low-density lipoproteins (10-11-10-12 M)[56] or even albumin (10-8 
M)[5, 57]. We selected three heme-specific sdAbs, i.e. 1A6, 2H7 and 2H10 (Fig. 1-3), with an affinity 
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towards soluble heme in the rage of 10-7 M (Fig. 1G). Analyzes of the structural properties of the 
sdAb 2H10 using Spectrophotometry, Resonance Raman and FITR, suggest that this sdAb interacts 
with heme via a cysteine at the fifth ligand and possibly a lysine or a tyrosine as the sixth axial ligand 
(Fig. 4C-F) [36]. Heme binding promotes conformational changes in the anti-parallel β-sheets of this 
sdAb to presumably accommodate heme (Fig. 4D-E).  
We found that heme recognition by heme-specific sdAbs is impaired as pH drops to 4-4.5 (Fig. 
5A,B) being also affected by Ca2+ but not by the Mg2+ or Fe2+ (Fig. 3B; Fig. 5 C,D), which is 
consistent with similar observations for heme binding by the plasma heme scavenger hemopexin 
(HPX) [42][58]. Of note, while heme is bound to HPX by two histidine residues that are protonated at 
low pH, there are no apparent histidine residues involved in heme binding by the SdAb tested and as 
such the mechanism via which lowering pH disables heme binding to the sdAb is not clear.  
We confirmed that heme accumulates in plasma during acute sterile hemolysis (Fig. 6B) and 
chronic hemolysis caused by Plasmodium infection (Fig. 7B) or by the sickle Hb (Fig. 8A). 
Approximately 2-8% of the heme detected in plasma (~2-5 µM) is bioavailable for internalization by 
bystander cells (Fig. 6D, 7E and 8C). Of note, heme is cytotoxic to parenchyma cells in this 
concentration range [10, 22-25, 59] arguing further for the participation of labile heme in the 
pathogenesis of these hemolytic conditions. Heme was not detected in plasma using the sdAb-based 
ELISA, suggesting that bioavailable heme is contained in a pool of labile heme bound to plasma 
molecules with an affinity > 10-7 M. 
While our data is consistent with the notion that hemolytic conditions are associated with the 
generation of labile heme bound to plasma molecules with higher affinity than 10-7 M, the identity of 
these heme-binding molecules is not clear. Presumably, a significant proportion of the labile heme is 
captured by HPX (0.6–1.2 mg/mL) and by lipoproteins, which bind heme with 10−12 M and 10-10-10-12 
M, respectively [23] but also by albumin (43 mg/mL) that has a lower affinity (10−8 M) towards heme. 
Given their affinity towards heme (10-8-10-12 M) these plasma proteins can capture heme from the 
heme-specific sdAb, as illustrated for HPX (Fig. 6G, H). This also explains why the heme-specific 
sdAb based ELISA does not detect labile heme in the plasma during different hemolytic conditions 
tested in this study. 
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Considering that adult mice have ~2mL of blood, ~10x109 RBC per mL and ~3x108 molecules of 
Hb per RBC, we estimated that 50-75% RBC lysis (Fig. 6A) should release ~10-15 mM of heme. This 
is consistent with the 30% decrease in HBC1/2 following acute hemolysis (Fig. 6I), likely attributed to 
the saturation of plasma HPX (~10-20 µM), high (~5-11 µM) and low-density (~0,04 µM) 
lipoproteins and albumin (~450-600 µM) [23, 54, 59, 60] by labile heme. In contrast to acute 
hemolysis, chronic hemolysis associated with the development of malaria (Fig. 7) or sickle cell 
anemia (Fig. 8) was not associated with a reduction of plasma HBC1/2 (Fig. 7D, 8B). Our 
interpretation is that a decrease in plasma HBC1/2 is only detectable in the event of rapid release of 
large amounts of labile heme, overcoming the HBC1/2 provided by high affinity plasma heme 
scavengers. Chronic hemolysis on the other hand is associated with a more gradual accumulation of 
labile heme in plasma, presumably allowing for regulatory mechanisms involving the expression of 
high affinity heme scavengers and the induction of heme catabolism by HO-1, as the means to prevent 
plasma HBC1/2 from reaching saturation and clear excess heme. This argues for a tight regulatory 
mechanisms restoring systemic heme homeostasis upon hemolysis. Nevertheless, malaria (Fig. 7) and 
sickle cell anemia (Fig. 8) were associated with the generation of bioavailable heme that can be 
readily internalized by bystander cells (Fig. 7E and 8C). Our data is consistent with the notion that at 
the levels detected in plasma, labile heme is likely to participate in the pathogenesis of hemolytic 
diseases. 
There are other methods that allow for the detection and characterization of labile heme in plasma, 
including a recently described reversed-high-performance liquid chromatography (HPLC)-based 
approach [61]. However, these approaches are less sensitive, as compared to the ones we describe 
herein, and moreover do not allow discriminating what proportion of the labile heme becomes 
bioavailable, which is made possible in our study based on the use of a cellular-based heme reporter 
assay [31, 62].  
Our study shows that heme-specific sdAbs can also be used to detect intracellular heme 
compartmentalization (Fig. 10 and 11), showing that in human cells the majority of intracellular heme 
probably localizes in the mitochondria, which is consistent with the last steps of heme synthesis 
taking place in the mitochondria.  A minor proportion of intracellular heme is also detected in the 
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endoplasmic reticulum of human cells (Fig. 11A) [31, 62]. This is consistent with previous studies 
showing that cellular labile heme concentration range at steady state from 20 to 40 nM and 2.5 nM in 
the cytoplasm and mitochondria of Saccharomyces cerevisiae, respectively [62]. The heme-specific 
sdAb also detected cellular heme in close vicinity of HO-1 (Fig. 11D) and bilirubin (Fig. 11E), a 
downstream end-product of heme catabolism. While consistent with the notion that the heme-specific 
sdAb recognize intracellular heme, we cannot prove that these react specifically with cellular labile 
heme. We are also aware that cellular fixation and permeabilization procedures do create changes in 
protein conformation and some level of protein unfolding, perhaps favoring the detection of loosely 
bound heme but also heme bound proteins with higher affinity. 
Ab recognizing heme or related metalloporphyrins have long been appreciated with several of 
these targeting ferric mesoporphyrin [63] and increasing [64] or reducing [65] its peroxidase activity. 
Consistent with these findings, binding of the sdAb 2H10 to soluble heme inhibits its peroxidase 
activity (Fig. 9A, B), which may provide a unique opportunity to prevent the pathogenic effects of 
labile heme during hemolytic conditions. Given that the affinity of hemopexin for heme (10-12M) is 
about 4-5 logs higher that that of the sdAb (10-7M) or albumin (10-8M), it is reasonable to assume that 
hemopexin should inhibit ascorbate oxidation with higher efficiency, as compared to the sdAb or to 
albumin. Because the sdAb 2H10 does not target related metalloporphyrins nor does it bind to heme 
when contained in Hb or other hemoproteins (Fig. 2 and 3) this should make its therapeutic use less 
toxic, as compared to approaches that target heme within hemoproteins, e.g. carbon monoxide [6, 23, 
66]. 
 
EXPERIMENTAL PROCEDURES 
Note: Except when indicated reagents were provide by Sigma (Sintra, Portugal). 
 
Tetrapyrrole preparation 
The concentration of different tetrapyrroles (Frontiers Scientific®, Utah, USA) was determined 
spectrophotometrically using appropriated solvents. Briefly, heme (i.e. hemin) was prepared in 0.1 M 
NaOH and buffered to pH 7.4 using 0.1 M HCl. Alternatively, hemin and other tetrapyrroles were 
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dissolved in dimethyl sulfoxide (DMSO) and concentration calculated using different wave lengths 
and extinction coefficients (EmM), i.e. hemin (λ405nm; EmM= 85,82), deuteroporphyrin IX (DeutP; λ392nm; 
EmM=170), gallium protoporphyrin (GaPP; λ413nm, EmM=249) [67], protoporphyrin (PP; λ408nm; 
EmM=297; in 1.5 M HCl) [67], Zinc protoporphyrin (ZnPP; λ415nm; EmM=150, in ethanol) [67]; 
biliverdin (BV; λ377nm; EmM=51,5, in methanol) [68] and bilirubin (BR; λ451nm, EmM=60, in chloroform 
[69]. Cobalt PP (CoPP), tin PP (SnPP) and FePP IX dimethyl ester chloride (FePPCH3) 
concentrations in DMSO were calculated gravimetrically according to their molecular weight (MW) = 
654.6, 750.26 and 679.99, respectively.  
 
Heme biotinylation  
Heme biotinylation was carried out essentially as described [70]. Briefly, hemin in 
dimethylformamide (DMF; 4.4 mg/mL) was incubated with 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluroniumhexafluorophosphate methanaminium and N,N-diisopropylethylamine (30-60 
min.; RT). N-[-5-(Hydrazinocarboxy) pentyl]-D-biotinamide (biotin) in DMSO was added (60 min.; 
RT) and the reaction was applied onto a C18 reverse-phase analytic HPLC column (COSMOSIL 
5C18-ARII, Nacalai Tesque, Nijo Karasuma, Japan) to separate biotinylated from non-biotinylated 
heme and biotin. Fractions were dried (SpeedVac Plus SC110A; Vaccum System Plus UV400A) at 
<15ºC.  
 
Matrix-assisted laser desorption/ionization (MALDI)-Time-of-flight mass spectrometry 
(TOFMS)  
Hemin and biotin in 0.2 M NaOH were spotted onto the MALDI target plate and mixed 1:1 with 2,5-
dihydroxybenzoic acid (DHB; 10 mg/mL) in 50% v/v acetonitrile, 5% v/v formic acid and air-dried. 
Heme-biotin in 50% (v/v) acetonitrile was spotted onto a MALDI plate using the Maldi matrix as 
described above. Data was acquired in positive reflector MS mode in a mass spectrometer (4800 plus 
MALDI-TOF/TOF; AB Sciex) and collected (4000 Series Explorer Software v.3.5.3; Applied 
Biosystems, California, USA). Mass spectrometer calibration was performed using angiotensin II 
(1046.542 Da), angiotensin I (1296.685 Da), Neurotensin (1672.918 Da), Adrenocorticotropic 
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hormone (ACTH) (1–17) (2093.087 Da) and ACTH (18–39) (2465.199 Da) (Peptide Calibration 
Mixture 1, LaserBio Labs, Sophia-Antipolis, France). Each reflector MS spectrum was collected 
using 500 laser shots per spectra and a fixed laser intensity of 3300 V.  
 
Phage library and selection [71]  
A synthetic VL sdAb phage display library previously used against several targets was used in our 
study [32]. The library repertoire (8x109 independent clones) was generated on a highly soluble and 
stable VL scaffold by randomization and accommodating a maximum of 26 aa in CDR1 and 22 aa in 
CDR3 [32]. The selection process was divided into four main steps: (i) incubation of phage-sdAb 
repertoire with heme-biotin; (ii) streptavidin capture and washing to remove non-specific phages-
sdAb; (iii) heme competition for phage-sdAb elution and (iv) amplification of antigen-specific 
phages-sdAb. Five rounds of binding, elution and amplification were performed to select sdAbs with 
high binding activities and specificity. Briefly, heme-biotin (1 µg/µL) was pre-incubated (2h; RT) 
with the sdAb VL phage library (1010/mL). The selection procedure consisted in using streptavidin 
coated magnetic beads (Dynabeads; M280) to capture phages bound to heme-biotin, under a magnetic 
field. Unbound or low affinity bound phages were washed out (Dulbecco's Phosphate Buffered Saline 
(PBS) 0.5% tween 20, 5x). Bound-phages were released from the heme-biotin with a competition step 
by addition of excess hemin (100 µM in PBS; 1h; RT; 2x). The recovered phages were used to infect 
E. coli ER2738 (phage display optimized strain; 600nm=0.6; Biocat; 4mL; 15-30 min. 37
oC). Phage-
infected ER2738 bacteria were grown in Super Broth (10 µg/mL tetracycline, 100 µg/mL ampicillin) 
and plated in Luria Broth (LB) agar (100 µg/mL Amp) at 37ºC. Single clones were randomly selected 
and screened by PCR to insure the presence of VL sequences. Bacteria growing in liquid medium 
were then infected with VCSM13 helper phages (1012-1013 pfu in 4 mL; 15-30 min.; 37oC), re-selected 
for kanamycin (100 µg/mL) resistance and left ON at 37ºC for phage production. After 16h, the 
selected phages were precipitated using PEG-8000 (4% w/v), NaCl (3% w/v) (1 h on ice), centrifuged 
(8000g; 30 min. 4oC), re-suspended (PBS, 15% Glycerol, 1 h in ice), centrifuged (16000g, 10-20 min. 
4oC) and filtered (0.22µm). The resulting “purified phages” were used for one additional panning with 
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ten washing cycles (PBS, 0.5% Tween 20) and three more additional panning with fifteen washing 
cycles (PBS 0.5% Tween 20). E. coli (TOP10F’ strain; 600nm=0.6) were infected with phages selected 
from the fourth panning (4mL; 15-30 min. 37oC), grown (Super Broth, 10 µg/mL tetracycline and 100 
µg/mL Amp), plated (LB agar, 100 µg/mL Amp) and VL sequences confirmed by PCR. Phage-
infected bacteria were grown (Super Broth, 10 µg/mL tetracycline and 100 µg/mL Amp, ON), the 
pComb3X phagemid DNA was extracted (Midi prep. Quiagen, Hilden, Germany), isolated and 
digested with SfiI (Fermentas, Portugal) for the extraction of DNA encoding sdAb fragments. These 
were purified from agarose gel electrophoresis, cloned into a modified pPT7-FLAG vector 
(Technophage SA, Lisboa, Portugal) and used to transform BL21 (DE3) E. coli (Promega, Wisconsin, 
USA). Bacterial clones were grown in auto induction medium (Novagen, Wisconsin, USA), lyzed 
(PBS, 20% Bugbuster, Novagen, ON, 4oC) and protein extracts were obtained (16000g, 15 min., 4oC) 
for selection of sdAb according to their heme binding capacity. 
 
SdAb expression and purification  
Twenty His-HA-tagged sdAbs were selected according to heme binding capacity and eleven of those 
were expressed and purified, essentially as described [32]. Briefly, the sdAbs cloned in a pPT7 
expression vector were transformed in E. coli BL21 (DE3) cells and sequences were confirmed 
(Macrogen DNA Sequencing service, Amsterdam, the Netherlands). For protein expression, one liter 
of LB, (50 µg/mL Carbenicillin) was inoculated with ON culture of bacterial cells (10 mL), 
transformed with pPT7-VL´s plasmids and grown (37ºC) to exponential phase (600nm=0.6-0.9). SdAb 
expression was induced by isopropyl β-1-thiogalactopyranoside (1mM; 6h, 37ºC). Bacteria were 
harvested by centrifugation (4000 g, 15 min., 4ºC) and re-suspended in equilibration buffer (50 mM 
HEPES, 1 M NaCl, 5 mM CaCl2, 10 mM imidazole, pH 7.8; 50 mL), supplemented with protease 
inhibitors (Roche, Amadora, Portugal). Bacteria were lysed by sonication (20 min., ice) and inclusion 
bodies containing the sdAbs were recovered by centrifugation (12096g, 30 min., 4ºC). Pellets were 
washed (50mM HEPES, 1M NaCl, 10mM imidazole, 5mM CaCl2, 2M urea, 1mM -mercaptoethanol 
(-ME); pH 7.8), sonicated (20 min., ice) and collected by centrifugation (12096g, 30 min., 4ºC). 
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Inclusion bodies were re-suspended in a 6 M Urea buffer (50mM HEPES, 1M NaCl, 10mM 
Imidazole, 5mM CaCl2, 6M urea, 1mM -ME, pH 8.0) containing benzonase (>250U, Sigma) and 
incubated ON (4ºC, under agitation) to allow for protein denaturation. SdAbs were purified under 
denaturing conditions using a His Trap Fast Flow (FF) column (GE Healthcare, Little Chalfont, 
United Kingdom) and washed twice (50 mM HEPES, 1M NaCl, 6M Urea, 1mM -ME, 5mM CaCl2, 
and 20 mM or 30 mM Imidazole; pH 7.8) to remove non specific protein contaminants. SdAb were 
eluted in high concentrated imidazole buffer (50 mM HEPES, 1M NaCl, 6M urea, 1mM -ME, 5mM 
CaCl2, 500 mM Imidazole, pH 7.8). Re-folding was achieved by step-wise dialysis, essentially as 
described [35]. Briefly, purified sdAb were dialyzed (24h, 4ºC) to Tris buffer (50 mM Tris-HCl, 1mM 
EDTA; 200 mM NaCl, 6M Urea, 10 mM -ME) and -ME was removed by dialysis (48h, 4ºC) to the 
same buffer without -ME, allowing thiol group oxidation and consequently disulfide bond 
formation. SdAbs were refolded by sequential dialysis (24h, 4ºC) to Tris buffer (50 mM Tris-HCl, 
1mM EDTA; 200 mM NaCl; 6M Urea), reducing Urea concentration step wise from 3, 2, 1, 0.5 and 0 
M. Dialyses to buffers containing 1M and 0.5M Urea were supplemented with 0.4 mM oxidized 
glutathione (GSSG) and 4 mM reduced glutathione (GSH) plus 400 mM L-arginine to promote 
protein refolding (30). SdAbs were centrifuged (4000g, 4ºC, 10 min.), to remove protein precipitates, 
aliquoted and stored (-80ºC) until used. SdAbs purity was assessed by Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel with 15% acrylamide under denaturing 
conditions followed by based Coomassie-based stain (Instant Blue, 30 min., RT, Gentaur, 
Kampenhout, Belgium.) and by Western blotting. 
 
SdAb biotinylation  
Briefly, sdAb where incubated with 20-fold molar excess of biotin (2h, ice) in PBS using EZ-Link 
NHS-PEG4-Biotinylation kit (Pierce by Thermofisher, Massachusetts, United States). Free biotin and 
free sdAb were removed using a desalting column (Thermo Zeba Spin Desalting column, Pierce) 
(1000g, 2 min.), pre-equilibrated in PBS. SdAb biotinylation was confirmed using 4'-
hydroxyazobenzene-2-carboxylic acid (HABA) assay. Briefly, biotinylated-sdAb was mixed (1/10) 
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with a HABA/Avidin (0.5 mg/mL avidin, 0.3 mM HABA, PBS) in a 96 well plate and 500nm 
measured in a microplate reader (Victor3 Multilabel Readers, Perkin Elmer). Biotinylated-sdAbs were 
stored at -80ºC until used. 
 
Western Blotting  
Proteins were subjected to 15% SDS-PAGE gel electrophoresis (15 V, 60 min.), transferred into 
methanol activated polyvinyldifluoridine membrane (2 min.), washed (3x in H2O, 3x T-TBS; 20 mM 
Tris pH 7.5, 150 mM, 0.05% Tween-20) and blocked (5%-skim milk in T-TBS; 1h, ON; RT). SdAbs 
were detected using a horseradish peroxidase (HRP)-conjugated rat anti-HA monoclonal Ab (mAb) 
(1/2000, Roche ®). Peroxidase activity was revealed using SuperSignal West Pico Chemiluminescent 
substrate (Pierce) in a photoradiograph (Kodak Biomax Light Film; Eastman Kodak, New York, 
USA). ExPASy - ProtParam tool was used to estimate the MW and isoelectronic point of sdAbs.  
ELISA  
Hemin (100 µM) in carbonate buffer (0.1M NaHCO3, pH 8.6) was used bound to 96 well plates 
(Costar 3690) (1h, RT or ON at 4ºC), washed (3x, PBS, 0.1% Tween 20), blocked in protein free 
blocking buffer (Pierce; 1h, RT) and washed (4x, PBS, 0.1% Tween 20). Bacterial supernatants or 
purified sdAbs were added (1h 30 min., RT, diluted in PBS), plates were washed (5x PBS, 0.1% 
Tween 20) and heme-bound sdAbs were detected using a rat anti-HA mAb (3F10; Roche; 0.1µg/mL) 
in protein-free blocking buffer. Plates were washed (5x PBS, 0.1% Tween 20) and the rat anti-HA 
mAb was detected using an alkaline phosphatase labeled rabbit anti-whole rat IgG (Sigma) polyclonal 
Ab (1 h, RT, 1/2000) in protein free blocking buffer. Alkaline phosphatase was revealed with para-
Nitrophenylphosphate (pNPP, 1mg/mL; Sigma). Absorbance was measured in a microplate reader at 
450nm (Victor
3 Multilabel Readers, Perkin Elmer). 
To measure the total amount of protein in sdAb supernatants, 96 well plates (Costar 3690, 
Sigma) were coated with the sdAb supernatant in 50 mM carbonate/bicarbonate buffer, pH 9.6 (1h, 
RT or 16h, 4ºC). The rest of the procedure was performed as described above. Absorbance was 
measured in a microplate reader at 450nm. 
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To measure labile heme, 96 well plates were coated with SdAb 1A6 (0.3-5 µg/mL) in 50 mM 
carbonate/bicarbonate buffer, pH 9.6 (16h, 4ºC), washed (5x, PBS 0.1% Tween 20) and blocked (2h, 
RT) with protein free blocking buffer. Plates were incubated with hemin (0.15-5 µM in PBS), used as 
standard or with plasma (1h 30 min., RT). Plates were washed (5x, PBS, 0.1% Tween 20) and heme 
was detected using biotinylated 2H7 sdAb (2.5-5 ng/µL) in PBS. Plates were washed (5x, PBS, 0.1% 
Tween 20) and biotinylated sdAb was detected using Alkaline phosphatase conjugated with 
ExtrAvidin (1/2500, Sigma) in protein blocking buffer. Plates were washed (5x, PBS 0.1% Tween 20) 
and Alkaline phosphatase was revealed using pNPP (1mg/mL; Sigma). Absorbance was measured in 
a microplate reader at 450nm. 
 
Biacore  
SdAbs affinity towards heme was determined using surface plasmon resonance (SPR) (BIAcore 2000, 
BIAcore Inc. by Ge Healthcare). Briefly, sdAbs were captured on a CM5 chip using amine coupling 
at ~800 resonance units (RU). Heme (0-3000 nM) was injected for 4 min and sdAb-bound heme was 
allowed to dissociate (10 min.) before matrix regeneration (10 mM Glycine, pH 2.5). The signal was 
subtracted from that of an immobilized cell to generate sensorgrams of the amount of bound heme as 
a function of time. The running buffer, HBS-P (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v 
Surfactant P20; BIAcore) was used for all sample dilutions. BIAcore kinetic evaluation software 
(version 3.1) was used to determine dissociation constant (KD) from the association and dissociation 
rates using a one-to-one binding model. An irrelevant sdAb was used as negative control. 
 
SdAb pull-down assay  
SdAb binding to soluble hemin was assessed by a pull-down assay. Briefly, sdAbs were incubated 
(5h, 4ºC, agitation) with heme-biotin and half of the reaction mixture was incubated (2h, RT, 
agitation) with of Streptavidin-Dynabeads (M-280 Streptavidin, Invitrogen by Thermofisher), 
previously blocked (5h, RT) with protein free blocking buffer (Pierce). Mixture was washed (3x; 5 
min.; PBS, 0.05% Tween 20) and magnetic beads were captured (5 min. magnetic field) according to 
the manufacture’s instructions. SdAbs-heme-biotin complexes were collected (1 min., magnetic field) 
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and incubated (20 min., 100ºC, agitation) in loading buffer (50mM Tris-HCl pH 6.8, 2%SDS, 10% 
Glycerol, 1% -ME, 12,5 mM EDTA, 0.02% Bromophenol blue) (pull-down). The other half of the 
reaction mixture was denatured (100ºC, 10 min.) in loading buffer. Proteins were applied into a 15% 
SDS-PAGE gel under denaturing conditions and stained with a Coomassie-based stain (Instant Blue, 
Gentaur, 30 min., RT). Alternatively, sdAb were detected by Western blotting using a rat anti-HA 
horseradish peroxidase (HRP) conjugated mAb (1/5000, Roche ®) (1h, RT). 
 
Hemopexin (HPX) 
Apo-HPX was isolated from rabbit serum, as described [10, 72](kind gift from Dr. Ann Smith, 
University of Missouri-K.C., Kansas City, MO). Binding of HPX to heme was confirmed by UV-Vis 
spectrophotometry of the apo-protein or heme-HPX complexes; the concentration of the protein and 
equimolar heme binding were quantified, as described [73].  
 
Heme/sdAb complexes  
SdAbs in PBS were incubated with 2x molar excess hemin in NaOH/HCl pH 7.4 (ON, 4ºC). Free 
heme and free sdAb were separated using a PD10 column (GEHealthcare) pre-equilibrated in PBS. 
Heme binding to the sdAb was confirmed spectrophotometrically. Concentration of sdAb-heme 
complex was determined using formic acid assay, as described bellow (total heme). Total amount of 
protein was determined using Quick Start Bradford Protein Assay (Biorad, California, USA), 
according to the manufacture’s instructions.  
 
Spectroscopy assays  
UV-Visible spectra were recorded (PerkinElmer Lambda 25, UV/Vis spectrometer) using a 
concentration of 10 µM of sdAb in PBS. Increasing amount of hemin in 0.1M NaOH (pH 7.4) were 
added and incubated (5 min.) before recording the next spectra. Resonance Raman (RR) spectra were 
obtained using Raman spectrometer (Join Yvon U1000) coupled to a confocal microscope equipped 
with 1,200 lines/mm grating and a liquid nitrogen-cooled back-illuminated charge coupled device 
(CCD) detector. The spectra of 40 µM protein bound to heme and 50 µM heme in PBS buffer were 
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obtained using a rotating cell (Hellma, Müllheim, Germany) to avoid photoreduction and measured 
with λ413nm excitation line from a Krypton ion laser (Coherent Innova 302) with 4.5 mW laser power 
and 60 s accumulation time, at RT; typically 10 spectra were co-added to improve signal to noise 
ratio. After polynomial background subtraction, spectra were subjected to component analysis to 
determine the bandwidths and positions, using in-house created software. Circular Dichroism (CD) 
Spectroscopy measurements were performed using a Jasco J-815 spectropolarimeter equipped with a 
Peltier-controlled thermostated cell support. CD spectra were recorded with sdAb 2H10 (240 μg/mL 
in 35% 50mM TRIS, 200 mM NaCl, 0.1 mM EDTA, 10% glycerol; pH 7.4 in PBS). Spectra were 
collected (50nm/min.) and acquired (10x) to improve the signal to noise ratio. Attenuated total 
reflectance (ATR) Fourier transform infrared (FTIR) spectra were measured on a Bruker IFS 66/S 
spectrometer equipped with a MCT detector and a thermostatized Harrick BioATR II cell. All 
measurements were obtained using an ATR cell with sdAb 2H10 (700 μg/mL in 50mM TRIS, 200 
mM NaCl, 0.1 mM EDTA, 10% glycerol at pH 7.4) dissolved in PBS (1x), with or without heme. 
Each spectrum comprises the mean of 150 scans taken at a resolution of 4 cm-1. Spectral assignments 
for specific secondary structure elements were made as in [41]. 
 
Mice 
Mice were maintained under SPF conditions and experiments approved by the Ethics Committee of 
the Instituto Gulbenkian de Ciência, Direção Geral de Alimentação e Veterinária (Decreto-Lei nº 
113/2013) and European legislation (Directive 2010/63/EU). C57BL/6J mice were obtained from the 
Instituto Gulbenkian de Ciência’s Animal Facility. C57BL/6xSv129 hα/hα::βA/βA, hα/hα::βA/βS and 
hα/hα::βS/βS mice [43] were obtained from Jackson laboratories (Reference 013071). 
 
pH titration 
To address the effect of pH on heme binding by sdAb, assays were performed, essentially as 
described [74]. Briefly, sdAb (10 µM in PBS) were allowed to bind hemin (10 µM; pH 7, 15-20 min, 
RT) and pH was titrated down to 4.0-4.5 using 0.5 M HCl and restored thereafter using 0.5M KOH 
(RT). To evaluate the effect of divalent cations, sdAbs bound to heme were first titrated down using 
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0.5 M HCl, followed by the addition of CaCl2 or MgCl2 (3 mM) at pH 4.0-4.5 and then the pH was 
titrated up to neutral using 0.5M KOH (RT). UV-visible spectra were recorded (PerkinElmer Lambda 
25, UV/Vis spectrometer). Background of the spectra was corrected using the software OriginPro 8®. 
 
Phenylhydrazine  
Adult C57BL/6 mice were injected (s.c.) with freshly prepared phenylhydrazine (Sigma) (1xPBS, 
pH7.4; 90 mg/Kg; body weight). 
 
Plasmodium infection  
Adult C57BL/6 mice were infected intraperitoneally (i.p.) with 2x106 Pcc AS strain per mouse and 
parasitemias were determined by Giemsa-stained blood smears and monitored daily, as described [22, 
24]. 
 
Mouse plasma  
Obtained by cardiac puncture (heparin or EDTA), centrifuged (2x; 1600g, 5min., 4ºC) and stored (-
80ºC). 
 
Total heme  
Heme concentration was measured essentially as described [75]. Briefly, samples were diluted in H2O 
in 96 well plates, formic acid (150 µL/well; 98-100%, Merck) was added and absorbance was 
measured at 405nm using a microplate reader (Victor
3 Multilabel Readers, Perkin Elmer). Heme 
concentration was determined by comparison to a hemin standard curve (0.5-16 µM in H2O).  
 
Bioavailable heme  
Bioavailable heme was measured using a previously described cellular heme reporter assay based on 
heme dependent HRP activity [12, 31]. Briefly, HEK293 cells (ATCC; 5x104 cells/well in a 24 well 
plate) were grown (ON; DMEM, 10% FBS, 1% penicillin 10000 U/mL, streptomycin 10000 µg/mL) 
and transiently transfected (4-6h, Lipofectamin 2000; Invitrogen) with an expression vector encoding 
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the HRP gene under the control of the EF-1 promoter (pEF5/FRT/V5-DEST-Golgi-HRP) in opti-
MEM reduced serum (Gibco by thermofisher) [12]. Expression of HRP was confined to the Golgi 
with a targeting sequence from galactosyltransferase [12, 31]. Control HEK293 cells were transiently 
transfected with the pEF5/FRT/V5-DEST vector [12, 31]. Transfected cells were cultured (24h) in 
DMEM (10% heme-depleted FBS) with or without succinylacetone (SA; 0.5 mM) to block 
endogenous heme synthesis. Cells were washed and treated with hemin (ON) in opti-MEM containing 
0.5 mM SA and peroxidase activity was assessed as a red-out of cellular heme content. Briefly, cells 
were lysed (20 mM HEPES pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 2,5X protease inhibitor 
cocktail set; Calbiochem®) (ice, 20 min.), centrifuged (13.500 rpm, 4ºC, 5min.) and peroxidase 
activity was quantified in a 96 well plate using 3,3’,5,’-Tetramethylbenzidine (TMB) substrate reagent 
set (BD OptEIA by thermofisher). Reaction was stopped (2N H2SO4) and absorbance was measured 
in a microplate reader at 450nm (Victor
3 Multilabel Readers, Perkin Elmer). Peroxidase activity was 
determined based on the calibration curve generated with the serial dilution of HRP (type IV, Sigma) 
and normalized to protein expression (Quick Start Bradford Protein Assay; Biorad). HRP 
concentration was determined based on Beer-Lambert law using the extinction coefficient (λ403nm; 
EmM=100). 
 
Heme depleted medium  
Depletion of heme from culture medium was performed as described [76]. Briefly, DMEM (Life 
Technologies) was supplemented with 10% heat inactivated fetal bovine serum (FBS; Life 
Technologies by Thermofisher) pre-depleted from heme using ascorbic acid (10 mM; 37ºC, 50 rpm) 
until λ405nm=0.6-0.8 (~7 h), dialyzed (3x) in sterile PBS and filtered (0.2µm). Final culture medium 
was supplemented with 1% penicillin (10000 U/mL) and streptomycin (10000 µg/mL).  
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Heme binding capacity (HBC1/2)  
The assay is based on the following principle: Plasma is incubated in vitro with increasing 
concentrations of heme (1h30, RT, agitation), until saturation of heme-binding molecules (with an 
affinity towards heme higher than 10-7 M). The heme-specific sdAb-based ELISA is used, as 
described above, to detect excess heme. The concentration of heme required to reduce by 50% the 
plasma heme-binding capacity is defined as HBC1/2. 
 
Heme competition assays  
SdAbs (2.5 µg/mL) were pre-incubated (90 min., RT, mild agitation) with tetrapyrroles or 
hemoproteins and used to detect solid-phase bound heme by ELISA, as described above. 
 
Ascorbate oxidation assay  
We adapted a previously described assay [77] as a readout for the oxidation activity of heme in the 
absence or presence of albumin or heme-specific sdAb. Briefly, the reaction was initiated by the 
addition of heme (0-5 µM), without or with protein/sdAb (0-5µM) and hydrogen peroxide (800µM), 
to ascorbate (10 µM) in PBS pH 7.4 containing a metal chelator DETAPAC (50 µM) that does not 
inhibit heme mediated oxidation. The reaction was carried out under air at 37ºC and after a certain 
time, stopped by the addition of one volume of 0.5% metaphosphoric acid to one volume of reaction 
mix. The final solution was centrifuged and the supernatant collected and analyzed using HPLC with 
electrochemical detection [78]. 
 
Heme-biotin pull-down assay 
SdAb 2H10 was incubated (30-60 min, 4ºC, agitation) with heme-biotin and HPX was added to the 
mixture at 1/6 SdAb/HPX molar ratio (30-60 min, 4ºC, agitation). To evaluate the ability of HPX to 
bind heme-biotin, HPX was incubated (30-60 min, 4ºC, agitation) with heme-biotin. Half of the 
reaction mixture was incubated (2h, RT, agitation) with Streptavidin-Dynabeads (M-280 Streptavidin, 
Invitrogen), previously blocked (5h, RT) with protein free blocking buffer (Pierce). The reaction 
mixture was washed (3x; 5 min.; PBS, 0.05% Tween 20), magnetic beads were captured (5 min. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
magnetic field) according to the manufacture’s instructions and incubated (20 min., 100ºC, agitation) 
in loading buffer (50mM Tris-HCl pH 6.8, 2%SDS, 10% Glycerol, 1% -ME, 12,5 mM EDTA, 
0.02% Bromophenol blue). The other half of the reaction mixture was denatured (100ºC, 10 min.) in 
loading buffer. Reaction mixtures in loading buffer were applied into a 15% SDS-PAGE gel under 
denaturing conditions and stained with a coomassie-based stain (Instant Blue, Gentaur, 30 min., RT). 
 
Intracellular heme detection by immunofluorescence 
HeLa (ATCC) cells were grown (24h) in DMEM (10% FBS, 1% penicillin 10000 U/mL, 
streptomycin 10000 µg/mL; Life Technologies), seeded onto coverslips in a 24 well plate until 80% 
confluence. Cells were washed (1x, PBS), incubated (5min., RT) in a hypotonic solution (85.5 mM 
NaCl, 5 mM MgCl2, pH 7.0), fixed (ice cold methanol, 10 min., -20ºC or 4% paraformaldehyde, 10 
min at RT), washed (1x, PBS), permeabilized (PBS, 0.1% triton X-100, 5 min.), washed (3x, PBS) 
and blocked (Protein-Free Blocking Buffer, Pierce, 1h, RT). For intracellular heme detection cells 
were incubated with heme-specific sdAbs (2,5 ng/µL; 3h, RT), washed (3x, blocking buffer) and 
incubated (1h, RT) with Alexa Fluor ®647 conjugated anti-HA Ab (clone 6E3; Cell Signaling 
Technology). Cells were washed (3x, PBS, 1x milli-Q Water), DNA was stained with DAPI (Sigma), 
dried and mounted with coversplips in Mowiol-Dabco media with DAPI. Images were acquired on a 
Leica DMRA2 upright microscope, equipped with a CoolSNAP HQ CCD camera, using a 100x 
1.4NA Oil immersion objective, DAPI + CY5 fluorescence filtersets, controlled with the MetaMorph 
V7.5.1/ software. The analysis was done with ImageJ (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014). When indicated 
cells were co-immunostained with an anti-Calnexin rabbit Ab, an integral endoplasmic reticulum 
protein (clone C4731, Sigma), anti-early endosome antigen 1 (EEA-1) rabbit Ab, to localize early 
endosomes, phalloidin–tetramethylrhodamine B isothiocyanate phalloidin, a toxin that binds F-actin 
(P1951, Sigma), anti-bilirubin mAb (A420, Dojindo) or anti-HO-1 polyclonal Ab (SPA-896, 
Stressgen). Mitochondria were stained with MitoTracker® Red (Life Technologies). Confocal Z-
series stacks were acquired on a Leica SP5 Live upright microscope, using a 63x 1.3NA Oil 
immersion objective, with DAPI + Fluorescein isothiocyanate (FITC) + CY5 or DAPI + 
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Tetramethylrhodamine (TRITC) + CY5 laser lines, and spectral detection adjusted for the emission of 
the respective fluorochromes, controlled with the Leica software. The analysis was done with ImageJ 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2014). 
 
Intracellular heme detection by flow cytometry  
 HeLa cells were tripsinized (0.05% Trypsin-EDTA, Life Technologies), washed (1x, PBS), fixed (ice 
cold methanol, 10 min., -20ºC), re-suspended, washed (1x, PBS), permeabilized (PBS, 0.1% triton X-
100,5 min.), washed (1x, PBS) and blocked (Protein-Free Blocking Buffer; Pierce) (1h, RT). 
Intracellular heme was detected using anti-heme sdAb (2.5 µg/mL in blocking buffer, 2h30min., RT, 
shaking) followed by Alexa Fluor® 647 conjugated HA-Tag (6E3) mouse mAb (1/200, Cell Signaling 
Technology). Cells were washed (1x, PBS), re-suspended (PBS) and acquired in a FACScan (Becton 
Dickinson) with CellQuest software (BD Biosciences). The analysis was done with FlowJo (Tree Star, 
Inc.). 
 
Statistical Analysis  
When comparing the means of more than two experimental groups, we used analysis of variance 
(ANOVA) and significance between groups was estimated using Bonferroni post-test, when Gaussian 
distribution was confirmed. For samples with non-Gaussian distribution, comparison between 
experimental groups was performed using a Kruskal-Wallis test, followed by post-test Dunns to 
compare all paired groups. Statistical analyses were performed using the GraphPad v.5.0a software 
(Prism), and p values were represented as *p < 0.05, ** p < 0.01, ***p<0.001. 
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Table 1: Summary of the sdAbs binding specificity against different tetrapyrroles. 
SdAbs 1A6, 2H7 and 2H10 recognize (+) or not (-) the different tetrapyrroles and some only 
when at higher concentration (+/-).  
 
 
 
  
 Tetrapyrroles 
sdAbs FePP PP GaPP ZnPP CoPP SnPP 
DeutP
P 
FePPC
H3 
BV BR 
1A6 + + + - + + + + +/- +/- 
2H7 + - + + + + + +/- +/- - 
2H1
0 
+ - + - + + + - - - 
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FIGURE 1. Selection of heme-binding sdAbs using phage display technology. (A) MALDI-
TOF/TOF analysis of biotinylated heme. Peak of mass-to-charge (m/z) 969.2 Da with characteristic 
isotopic cluster pattern, corresponding to biotinylation of a single hemin carboxylic acid residue. (B) 
Schematic representation (Accelrys draw 4.1 and 3D representations; Pymol software) of heme and 
biotinylated heme. (C) Elution cycles outputs of bacteria infected with phages displaying sdAbs 
recognizing heme. (D) Ratio of heme binding to protein expression of 1721 sdAb (circles) screened 
by ELISA, as described in Experimental Procedures. SdAbs 2H10, 2H7 and 1A6, with highest heme 
binding to protein expression ration, are highlighted. (E) SDS-PAGE of purified sdAbs stained by 
coomassie based stain or detected by western blot using an anti-HA mAb. (F) ELISA for recognition 
of solid-phase heme by purified sdAb. Ctrl: Control sdAb that does not recognize heme. (G) SdAb 
CDR1 aminoacid sequences, as determined by DNA sequencing. Binding affinity of SdAbs towards 
heme, determined by BIAcore surface Plasmon resonance. 
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FIGURE 2. Assessment of sdAbs specificity against heme vs. related tetrapyrroles. Inhibitory 
effect of pre-incubation of sdAb with increasing concentrations of (A) FePP, PP or GaPP, (B) FePP, 
DeutP or FePPCH3, (C) biliverdin (BV) or bilirubin (BR) on sdAb binding to solid phase bound 
heme, measured by ELISA. Data from one out of three independent experiments with similar trend is 
shown. 
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FIGURE 3. Assessment of sdAbs specificity against heme vs. heme analogs or heme contained in 
hemoproteins. Inhibitory effect of pre-incubation of sdAb with increasing concentrations of (A) 
FePP, ZnPP, CoPP or SnPP, (B) FePP or Fe2 (SO4)3 (C) FePP, Hb, oxidized Hb (MetHb), Myoglobin 
(Mb), Cytochrome c (Cytc) or human serum albumin bound to heme (HSAH), measured by ELISA. 
Data from one out of three independent experiments with similar trend is shown. 
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FIGURE 4. Analysis of heme binding by SdAbs. (A)  SdAbs bound to biotinylated heme in solution 
were pooled-down using streptavidin (SA) beads and detected by western blot using anti-HA mAb. 
Input was measured by Coomassie-based stain. (B) UV-Visible spectra of hemin. Soret region at 
approximately 364 nm and 383 nm and a CT band at 622 nm are shown, representative of three 
independent experiments. (C) UV-visible spectra of sdAb 2H10, 1A6 and 2H7 bound to heme at 
different concentrations. Soret (412 nm), Q1 (530 nm), Q0 (565 nm) and CT (624 nm) bands are 
highlighted. (D) Far UV CD spectra of sdAb 2H10 in the apo (black) and heme-bound (red) forms. 
Shift from 212 to 218 is due to heme-driven conformational rearrangement of the sdAb secondary 
structure. The inset shows the Soret region, with the appearance of the 412 nm band, due to heme 
binding to the sdAb. (E) ATR FTIR absorption spectra (top) and second derivative (bottom) of sdAb 
2H10 in the apo (black) and heme-bound (red) forms in the amide I region (1700-1610 cm-1), showing 
structural modification upon heme coordination. (F) High frequency Resonance Raman spectra of 
hemin and sdAb 2H10 bound to hemin, obtained with 413 nm excitation. 
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FIGURE 5. Effect of the pH and divalent cations on heme binding by sdAb. (A) UV-visible 
spectra of heme binding by sdAb 2H10 bound under gradual pH decrease by the addition of HCl. (B) 
UV-visible spectra of sdAb 2H10 bound to heme under gradual pH neutralization by the addition of 
KOH. (C) UV-visible spectra of sdAb 2H10 bound to heme under gradual pH neutralization by the 
addition of KOH in the presence of calcium (Ca2+; 3mM) or (D) magnesium (Mg2+; 3mM). The 
divalent cations Ca2+ impair the binding of the sdAb to heme contrarily to the magnesium (Mg2+). 
Data is representative of three independent experiments with similar trend.  
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FIGURE 6. Characterization of labile heme in plasma following acute hemolysis. (A) Number of 
RBC in C57BL/6 mice receiving Phenylhydrazine (PHX) and control (CTRL) mice receiving PBS. 
(B) Heme concentration in the plasma of C57BL/6 mice receiving phenylhydrazine. (C) Correlation 
between circulating RBC numbers (data from A) and heme concentration in plasma (data from B) in 
C57BL/6 mice receiving phenylhydrazine. (D) Concentration of bioavailable heme in plasma of 
C57BL/6 mice receiving phenylhydrazine, quantified by a heme reporter assay [31]. (E) Correlation 
between circulating RBC numbers (data from A) and concentration of bioavailable heme in plasma 
(data from D) in C57BL/6 mice receiving phenylhydrazine. (F) Soluble hemin quantified by a 
sandwich ELISA in which the sdAbs 1A6 and 2H7 are used to capture and reveal heme, respectively. 
(G) Detection of soluble heme vs. heme bound to HPX using the same sdAb-based ELISA as in (F). 
The sdAb-sandwich based ELISA was used to verify whether the sdAbs can recognize heme bound to 
HPX. This assay reveals that heme bound to HPX is not detected by the sdAbs. (H)  A pull-down 
assay using streptavidin-beads and heme-biotin was used to demonstrate that heme-biotin bound to 
sdAb 2H10 can be removed by HPX. To the 2H10 SdAb bound to heme-biotin was added HPX (1/6 
SdAb/HPX molar ratio) and then heme biotin bound protein was pulled-down using streptavidin-
beads. Streptavidin-beads pulled-down the sdAb 2H10 as well as HPX bound to heme-biotin, 
demonstrating once more the ability of HPX to bind to heme-bound to sdAb 2H10. The data obtained 
in both assay is consistent with the higher affinity of HPX towards heme as compared to the sdAb 
2H10. Coomassie-based stain of 15% SDS-PAGE gel loaded with streptavidin-beads used to pull-
down heme-biotin from different reaction mixtures composed of 2H10 sdAb and/or HPX and/or 
heme-biotin. Grey arrowheads indicate the molecular weight of the protein ladder (NZYColour 
Protein Marker II, Nzytech ®) in kDa loaded in the first lane of the gel. Gel is representative of two 
independent experiments with similar trend. (I) Plasma HBC1/2 in C57BL/6 mice receiving 
phenylhydrazine. Circles in A, B, C, D, E and I correspond to individual mice. Each circle 
corresponds to an individual mouse. Red dash line represents mean ± STD. *p<0.05, ** p<0.01, 
***p<0.001 versus time 0, calculated by ANOVA and Dunns post-test.  
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FIGURE 7. Characterization of labile heme in plasma following Plasmodium infection. (A) 
Percentage of infected RBC (iRBC) and (B) heme concentration in plasma of C57BL/6 mice (n=4-5) 
infected with Pcc . (C) Correlation between percentage of iRBC (data from A) and heme 
concentration in plasma (data from B). (D) HBC1/2 in Pcc infected C57BL/6 mice. (E) Bioavailable 
heme in Pcc infected C57BL/6 mice. (F) Correlation between the percentage of iRBC (data from A) 
and bioavailable heme (data from E). *p<0.05 and ** p<0.01 versus time 0, established by ANOVA 
and Dunns post-test. Circles correspond to individual mice. Red dash line represents mean from mice 
pooled from 2-3 independent experiments with similar trend. 
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FIGURE 8. Heme accumulation in plasma in sickle-cell disease. (A) Total heme, (B) HBC1/2 and 
(C) bioavailable heme in sickle hα/hα::βS/βS versus control hα/hα::βA/βA and hα/hα::βA/βS mice. *p < 
0.05 established by ANOVA and Dunns post-test. Each circle corresponds to an individual mouse. 
Red dash line represents mean ± STD.  
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FIGURE 9. Targeting heme with sdAbs. Ascorbate oxidation by heme in the presence or absence of 
sdAb 2H10, control (Ctrl) sdAb or human serum albumin (HSA) under (A) increasing heme or (B) 
protein concentrations. Results shown are the mean ± SEM from four (A) and three (B) independent 
experiments. *** Mean value of sdAb 2H10 differs from the corresponding mean point value of Ctrl 
sdAb at the p < 0.001.  
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FIGURE 10. Detection of intracellular heme using sdAbs. (A) Intracellular heme (red) and DNA 
(blue) in HeLa cells, detected by immunoflurescence using different heme-specific sdAbs and DAPI, 
respectively. Staining with a control sdAb (Ctrl) that does not recognize heme, is shown. Scale bar, 10 
µM. Arrows highlight heme staining. (B) Detection of intracellular heme by flow cytometry in HeLa 
cells, using the same sdAbs as in (A). (C) Same as (B), with pre-incubation of sdAb 2H10 with 
increasing concentrations (0-160 µM) of hemin in solution. (D) Same as (A), using sdAb 2H10 pre-
incubated or not with hemin (160 µM) in solution. (E) Same as (C), with sdAb 2H10 pre-incubated 
with heme (160 µM) or PP (160 µM). (F) Same as (A), in HeLa cells co-stained with MitoTracker® 
for mitochondria localization (Green). Heme was detected using the sdAb 2H10 (red) and DNA with 
DAPI (blue). Merged images show co-localization of heme with mitochondria (yellow). For each 
condition Z-stacks were acquired and orthogonal view (OV) of the dashed line is shown. Arrows 
highlight co-localization. All images with a scale bar, 10 µm. Data in A-D are representative of three 
independent experiments with similar trend. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
FIGURE 11. Detection of intracellular heme using sdAbs. Heme (red) and DNA (blue) detected by 
immunofluorescence in HeLa cells using the sdAb 2H10 and DAPI, respectively. Cells were co-
stained (green) with (A) anti-Calnexin for endoplasmatic reticulum (ER) (B) anti-EEA-1 for 
endosomes, (C) a phalloidin–tetramethylrhodamine B isothiocyanate for F-actin, (D) anti-HO-1 
polyclonal Ab and (E) anti-bilirubin mAb. Merged figures show co-localizations (yellow). For each 
condition Z-stacks were acquired and orthogonal view (OV) of the dashed line is shown. Arrows 
highlight co-localization. Data shown is representative of three independent experiments with similar 
results. All images with a scale bar, 10 µm.  
 
